SMARTER INVESTMENT IN THE RESEARCH LONG GAME Government support for health and medical researchers and innovators needing investment cycle review
With
Nadia Levin, CEO
Research Australia
OP-ED SEGMENT
Filmed in Sydney | April 2026
In this Op-Ed, Nadia Levin, CEO of Research Australia, spoke with the Australian Health Journal about the need for smarter and more strategic investment in Australia’s health and medical research sector.
Levin argued that Australia’s approach to health and medical research has been shaped too heavily by short-term political cycles rather than a long-term national vision. She emphasised that meaningful progress in science, innovation, and healthcare requires sustained investment over many years.
According to Levin, health and medical research should not be viewed simply as a social good, but as a major driver of economic growth, productivity, and national resilience. She highlighted that every preventable hospital admission, faster diagnosis, or locally developed medical product contributes to economic performance.
Research Australia estimates that for every dollar invested in health and medical research, the Australian economy receives around four dollars in return.
Levin pointed to Australia’s past achievements, including the development of IVF, the cochlear implant, the HPV vaccine, and ultrasound imaging, as examples of how research can improve lives while creating industries and export opportunities.
A major focus in the need to strengthen the entire research pipeline, from early-stage discovery through to clinical translation, commercialisation, and integration into healthcare systems. Research Australia in a media release March 2026, noted that while the Medical Research Future Fund was created to distribute around $1 billion annually, it is currently providing only about $650 million each year despite holding approximately $24.5 billion.
Levin referenced costings from the Parliamentary Budget Office (PBO), commissioned by Dr Monique Ryan MP, showing the fund could distribute up to $1.4 billion annually without reducing its capital base, arguing that the money, demand, and need already exist, but stronger government commitment is required.
Source: Adapted from Research Australia media release March 2026
-
WA and QLD RSV Immunisation programs show drops in infant hospitalisations
RSV is the number one cause of hospitalisation of Australian children under five years of age, according to the Immunisation Foundation of Australia (IFA). There are mounting concerns that Australians at greatest risk of severe Respiratory Syncytial Virus, or RSV will miss out on protection against the lung infection, with the Federal Government failing to commit to a national RSV immunisation program.
-
Recognising service in health regulation
In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
-
Allied Health Building Leadership Experience in Tasmania
A notable program run by Hospitals South is the ABLE program, or Allied Health Building Leadership Experience. This program was created to address the challenge of allied health professionals being seen as a single entity, rather than as individual disciplines, when it comes to leadership and management opportunities. The program is delivered entirely internally, with seminars presented by senior staff and mentorship opportunities for participants to become more effective representatives of allied health in meetings and working groups.
